Table of Contents Author Guidelines Submit a Manuscript
International Journal of Chronic Diseases
Volume 2014 (2014), Article ID 327640, 17 pages
http://dx.doi.org/10.1155/2014/327640
Research Article

p21WAF1/CIP1 Expression is Differentially Regulated by Metformin and Rapamycin

Renal Unit and Diabetes Clinical Research Unit, Derriford Hospital, Plymouth, PL6 8DH, UK

Received 4 December 2013; Revised 3 February 2014; Accepted 13 February 2014; Published 25 March 2014

Academic Editor: Benjamin Kefas

Copyright © 2014 Zoltan Molnar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Adeghate, P. Schattner, and E. Dunn, “An update on the etiology and epidemiology of diabetes mellitus,” Annals of the New York Academy of Sciences, vol. 1084, no. 1, pp. 1–29, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. Z. Cao and M. E. Cooper, “Pathogenesis of diabetic nephropathy,” Journal of Diabetes Investigation, vol. 2, no. 4, pp. 243–247, 2011. View at Publisher · View at Google Scholar
  3. M. Kitada, Z. Zhang, A. Mima, and G. L. King, “Molecular mechanisms of diabetic vascular complications,” Journal of Diabetes Investigation, vol. 1, no. 3, pp. 77–89, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Arya, S. Aggarwal, and H. N. Yadav, “Pathogenesis of diabetic nephropathy,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 2, no. 4, pp. 24–29, 2010. View at Google Scholar · View at Scopus
  5. G. Wolf, “Molecular mechanisms of diabetic mesangial cell hypertrophy: a proliferation of novel factors,” Journal of the American Society of Nephrology, vol. 13, no. 10, pp. 2611–2613, 2002. View at Google Scholar · View at Scopus
  6. S. V. Griffin and S. J. Shankland, “Not just an inhibitor: a role for p21 beyond the cell cycle—“the truth is rarely pure and never simple”,” Journal of the American Society of Nephrology, vol. 15, no. 3, pp. 825–826, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. M. M. Poplawski, J. W. Mastaitis, F. Isoda, F. Grosjean, F. Zheng, and C. V. Mobbs, “Reversal of diabetic nephropathy by a ketogenic diet,” PLoS ONE, vol. 6, no. 4, Article ID e18604, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Satriano, H. Mansoury, A. Deng et al., “Transition of kidney tubule cells to a senescent phenotype in early experimental diabetes,” The American Journal of Physiology: Cell Physiology, vol. 299, no. 2, pp. C374–C380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Zheng, S. A. Whitman, W. Wu et al., “Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy,” Diabetes, vol. 60, no. 11, pp. 3055–3066, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Lieberthal and J. S. Levine, “The role of the mammalian target of rapamycin (mTOR) in renal disease,” Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2493–2502, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Haneda, D. Koya, M. Isono, and R. Kikkawa, “Overview of glucose signaling in mesangial cells in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 14, no. 5, pp. 1374–1382, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. V. P. Houde, S. Brûlé, W. T. Festuccia et al., “Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue,” Diabetes, vol. 59, no. 6, pp. 1338–1348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Inoki, “Role of TSC-mTOR pathway in diabetic nephropathy,” Diabetes Research and Clinical Practice, vol. 82, no. 1, pp. S59–S62, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Vodenik, J. Rovira, and J. M. Campistol, “Mammalian target of rapamycin and diabetes: what does the current evidence tell us?” Transplantation Proceedings, vol. 41, no. 6, pp. S31–S38, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. M. Miller, J. R. Brestoff, C. B. Phelps, E. Z. Berk, and T. H. Reynolds IV, “Rapamycin does not improve insulin sensitivity despite elevated mammalian target of rapamycin complex 1 activity in muscles of ob/ob mice,” The American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 295, no. 5, pp. R1431–R1438, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Mori, K. Inoki, K. Masutani et al., “The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential,” Biochemical and Biophysical Research Communications, vol. 384, no. 4, pp. 471–475, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Kalender, A. Selvaraj, S. Y. Kim et al., “Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner,” Cell Metabolism, vol. 11, no. 5, pp. 390–401, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Wang, X. Pan, and J. Song, “AMP-activated protein kinase is required for induction of apoptosis and epithelial-to-mesenchymal transition,” Cellular Signalling, vol. 22, no. 11, pp. 1790–1797, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. R. Owen, E. Doran, and A. P. Halestrap, “Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain,” Biochemical Journal, vol. 348, no. 3, pp. 607–614, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. B. A. Kefas, Y. Cai, K. Kerckhofs et al., “Metformin-induced stimulation of AMP-activated protein kinase in β-cells impairs their glucose responsiveness and can lead to apoptosis,” Biochemical Pharmacology, vol. 68, no. 3, pp. 409–416, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Viollet, B. Guigas, N. Sanz Garcia, J. Leclerc, M. Foretz, and F. Andreelli, “Cellular and molecular mechanisms of metformin: an overview,” Clinical Science, vol. 122, no. 6, pp. 253–270, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Ruggenenti and G. Remuzzi, “Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology same treatment?” Nephrology Dialysis Transplantation, vol. 15, no. 12, pp. 1900–1902, 2000. View at Google Scholar · View at Scopus
  23. L. Wu and R. Derynck, “Essential role of TGF-β signaling in glucose-induced cell hypertrophy,” Developmental Cell, vol. 17, no. 1, pp. 35–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. C. L. Buller, C. W. Heilig, and F. C. Brosius III, “GLUT1 enhances mTOR activity independently of TSC2 and AMPK,” The American Journal of Physiology: Renal Physiology, vol. 301, no. 3, pp. F588–F596, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. J. I. Kreisberg and S. H. Ayo, “The glomerular mesangium in diabetes mellitus,” Kidney International, vol. 43, no. 1, pp. 109–113, 1993. View at Google Scholar · View at Scopus
  26. M. Zakikhani, M.-J. Blouin, E. Piura, and M. N. Pollak, “Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells,” Breast Cancer Research and Treatment, vol. 123, no. 1, pp. 271–279, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. R. J. O. Dowling, M. Zakikhani, I. G. Fantus, M. Pollak, and N. Sonenberg, “Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells,” Cancer Research, vol. 67, no. 22, pp. 10804–10812, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Tosca, C. Ramé, C. Chabrolle, S. Tesseraud, and J. Dupont, “Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells,” Reproduction, vol. 139, no. 2, pp. 409–418, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Zhuang and W. K. Keith, “Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1,” Journal of Molecular Signaling, vol. 3, article 18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. S. O. Marx, T. Jayaraman, L. O. Go, and A. R. Marks, “Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells,” Circulation Research, vol. 76, no. 3, pp. 412–417, 1995. View at Google Scholar · View at Scopus
  31. J. W. Russell, D. Golovoy, A. M. Vincent et al., “High glucose-induced oxidative stress and mitochondrial dysfunction in nuerons,” FASEB Journal, vol. 16, no. 13, pp. 1738–1748, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. D. C. Han, M. Isono, B. B. Hoffman, and F. N. Ziyadeh, “High glucose stimulates proliferation and collagen type I synthesis in renal cortical fibroblasts: Mediation by autocrine activation of TGF-β,” Journal of the American Society of Nephrology, vol. 10, no. 9, pp. 1891–1899, 1999. View at Google Scholar · View at Scopus
  33. M. V. Rocco, Y. Chen, S. Goldfarb, and F. N. Ziyadeh, “Elevated glucose stimulates TGE-β gene expression and bioactivity in proximal tubule,” Kidney International, vol. 41, no. 1, pp. 107–114, 1992. View at Google Scholar · View at Scopus
  34. G. Wolf, K. Sharma, Y. Chen, M. Ericksen, and F. N. Ziyadeh, “High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-β,” Kidney International, vol. 42, no. 3, pp. 647–656, 1992. View at Google Scholar · View at Scopus
  35. F. N. Ziyadeh, K. Sharma, M. Ericksen, and G. Wolf, “Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β,” Journal of Clinical Investigation, vol. 93, no. 2, pp. 536–542, 1994. View at Google Scholar · View at Scopus
  36. Y.-J. Choi, H.-S. Lim, J.-S. Choi et al., “Blockade of chronic high glucose-induced endothelial apoptosis by Sasa borealis bamboo extract,” Experimental Biology and Medicine, vol. 233, no. 5, pp. 580–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Duffy, A. Liew, J. O'Sullivan, G. Avalos, A. Samali, and T. O'Brien, “Distinct effects of high-glucose conditions on endothelial cells of macrovascular and microvascular origins,” Endothelium-Journal of Endothelial Cell Research, vol. 13, no. 1, pp. 9–16, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. S. McGinn, S. Saad, P. Poronnik, and C. A. Pollock, “High glucose-mediated effects on endothelial cell proliferation occur via p38 MAP kinase,” The American Journal of Physiology: Endocrinology and Metabolism, vol. 285, no. 4, pp. E708–E717, 2003. View at Google Scholar · View at Scopus
  39. J.-D. Liu, Y.-J. Wang, C.-H. Chen et al., “Molecular mechanisms of G0/G1 cell-cycle arrest and apoptosis induced by terfenadine in human cancer cells,” Molecular Carcinogenesis, vol. 37, no. 1, pp. 39–50, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. C. C. Williams, B. A. Singleton, S. D. Llopis, E. V. Skripnikova, L. Jack Jr., and K. Kennedy, “Metformin induces a senescence-associated gene signature in breast cancer cells,” Journal of Health Care for the Poor and Underserved, vol. 24, no. 1, pp. 93–103, 2013. View at Publisher · View at Google Scholar
  41. A. Tzatsos and P. N. Tsichlis, “Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794,” Journal of Biological Chemistry, vol. 282, no. 25, pp. 18069–18082, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. B. Guigas, D. Detaille, C. Chauvin et al., “Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study,” Biochemical Journal, vol. 382, no. 3, pp. 877–884, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. A. L. Edinger, C. M. Linardic, G. G. Chiang, C. B. Thompson, and R. T. Abraham, “Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells,” Cancer Research, vol. 63, no. 23, pp. 8451–8460, 2003. View at Google Scholar · View at Scopus
  44. C. U. Niesler, K. H. Myburgh, and F. Moore, “The changing AMPK expression profile in differentiating mouse skeletal muscle myoblast cells helps confer increasing resistance to apoptosis,” Experimental Physiology, vol. 92, no. 1, pp. 207–217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. M. M. Shaw, W. K. Gurr, R. J. McCrimmon, D. F. Schorderet, and R. S. Sherwin, “5′AMP-activated protein kinase α deficiency enhances stress-induced apoptosis in BHK and PC12 cells,” Journal of Cellular and Molecular Medicine, vol. 11, no. 2, pp. 286–298, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. M. L. Coleman, C. J. Marshall, and M. F. Olson, “Ras promotes p21Waf1/Cip1 protein stability via a cyclin D1-imposed block in proteasome-mediated degradation,” The EMBO Journal, vol. 22, no. 9, pp. 2036–2046, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Moreno, R. Viana, and P. Sanz, “Two-hybrid analysis identifies PSMD11, a non-ATPase subunit of the proteasome, as a novel interaction partner of AMP-activated protein kinase,” International Journal of Biochemistry and Cell Biology, vol. 41, no. 12, pp. 2431–2439, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Viana, C. Aguado, I. Esteban et al., “Role of AMP-activated protein kinase in autophagy and proteasome function,” Biochemical and Biophysical Research Communications, vol. 369, no. 3, pp. 964–968, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. V. Y. Yazbeck, D. Buglio, G. V. Georgakis et al., “Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma,” Experimental Hematology, vol. 36, no. 4, pp. 443–450, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. A.-M. Gabeni, C. Saucier, M. Bedini, V. Barbu, and J. Mester, “Rapamycin inhibits cdk4 activation, p21Waf1/Cip1 expression and G1-phase progression in transformed mouse fibroblasts,” International Journal of Cancer, vol. 108, no. 2, pp. 200–206, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. F. C. Brosius III, C. C. Khoury, C. L. Buller, and S. Chen, “Abnormalities in signaling pathways in diabetic nephropathy,” Expert Review of Endocrinology and Metabolism, vol. 5, no. 1, pp. 51–64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. C. L. Buller, R. D. Loberg, M.-H. Fan et al., “A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression,” The American Journal of Physiology: Cell Physiology, vol. 295, no. 3, pp. C836–C843, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Inoki, M. Haneda, S. Maeda, D. Koya, and R. Kikkawa, “TGF-β1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells,” Kidney International, vol. 55, no. 5, pp. 1704–1712, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Osterby, “Glomerular structural changes in Ttype 1 (insulin-dependent) diabetes mellitus: causes, consequences, and prevention,” Diabetologia, vol. 35, no. 9, pp. 803–812, 1992. View at Google Scholar · View at Scopus
  55. G. Wolf, “Cell cycle regulation in diabetic nephropathy,” Kidney International, Supplement, vol. 58, no. 77, pp. S59–S66, 2000. View at Google Scholar · View at Scopus
  56. T. Monkawa, K. Hiromura, G. Wolf, and S. J. Shankland, “The hypertrophic effect of transforming growth factor-β is reduced in the absence of cyclin-dependent kinase-inhibitors p21 and p27,” Journal of the American Society of Nephrology, vol. 13, no. 5, pp. 1172–1178, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Wolf, R. Reinking, G. Zahner, R. A. K. Stahl, and S. J. Shankland, “Erk 1,2 phosphorylates p27Kip1: functional evidence for a role in high glucose-induced hypertrophy of mesangial cells,” Diabetologia, vol. 46, no. 8, pp. 1090–1099, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Megyesi, P. M. Price, E. Tamayo, and R. L. Safirstein, “The lack of a functional p21Waf1/Cip1 gene ameliorates progression to chronic renal failure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 19, pp. 10830–10835, 1999. View at Google Scholar · View at Scopus
  59. M. V. Blagosklonny, “Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging,” Aging-Us, vol. 4, no. 3, pp. 159–165, 2012. View at Google Scholar
  60. C. Deng, P. Zhang, J. W. Herper, S. J. Elledge, and P. Leder, “Mice lacking p21(CIP1/WAF1) undergo normal development, but are defective in G1 checkpoint control,” Cell, vol. 82, no. 4, pp. 675–684, 1995. View at Google Scholar · View at Scopus
  61. G. Soria and V. Gottifredi, “PCNA-coupled p21 degradation after DNA damage: the exception that confirms the rule?” DNA Repair, vol. 9, no. 4, pp. 358–364, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. M. M. Kavurma and L. M. Khachigian, “Sp1 inhibits proliferation and induces apoptosis in vascular smooth muscle cells by repressing p21Waf1/Cip1 transcription and cyclin D1-Cdk4-p21Waf1/Cip1 complex formation,” Journal of Biological Chemistry, vol. 278, no. 35, pp. 32537–32543, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. A. G. Muntean, L. Pang, M. Poncz, S. F. Dowdy, G. A. Blobel, and J. D. Crispino, “Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization,” Blood, vol. 109, no. 12, pp. 5199–5207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Féliers, M. A. Frank, and D. J. Riley, “Activation of cyclin D1-Cdk4 and Cdk4-directed phosphorylation of RB protein in diabetic mesangial hypertrophy,” Diabetes, vol. 51, no. 11, pp. 3290–3299, 2002. View at Google Scholar · View at Scopus
  65. Y. Jiang, D. W. Cheng, E. Levi, and L. P. Singh, “IGF-1 increases laminin, cyclin D1, and P21Cip1 expression in glomerular mesangial cells: An investigation of the intracellular signaling pathway and cell-cycle progression,” Journal of Cellular Biochemistry, vol. 98, no. 1, pp. 208–220, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Tamamori-Adachi, H. Ito, K. Nobori et al., “Expression of cyclin D1 and CDK4 causes hypertrophic growth of cardiomyocytes in culture: a possible implication for cardiac hypertrophy,” Biochemical and Biophysical Research Communications, vol. 296, no. 2, pp. 274–280, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. H. Motoshima, B. J. Goldstein, M. Igata, and E. Araki, “AMPK and cell proliferation—AMPK as a therapeutic target for atherosclerosis and cancer,” Journal of Physiology, vol. 574, no. 1, pp. 63–71, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. Y.-N. Fu, H. Xiao, X.-W. Ma, S.-Y. Jiang, M. Xu, and Y.-Y. Zhang, “Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation,” Acta Pharmacologica Sinica, vol. 32, no. 7, pp. 879–887, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. K. R. Laderoute, K. Amin, J. M. Calaoagan et al., “5′-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments,” Molecular and Cellular Biology, vol. 26, no. 14, pp. 5336–5347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Safayhi, H. Haase, U. Kramer et al., “L-type calcium channels in insulin-secreting cells: biochemical characterization and phosphorylation in RINm5F cells,” Molecular Endocrinology, vol. 11, no. 5, pp. 619–629, 1997. View at Google Scholar · View at Scopus
  71. A. Danchin and H. Buc, “Proton magnetic resonance studies on 5′- AMP site in glycogen phosphorylase b,” FEBS Letters, vol. 22, no. 3, pp. 289–293, 1972. View at Google Scholar · View at Scopus
  72. S. A. Hawley, A. E. Gadalla, G. S. Olsen, and D. Grahame Hardie, “The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism,” Diabetes, vol. 51, no. 8, pp. 2420–2425, 2002. View at Google Scholar · View at Scopus
  73. K. Kishi, T. Yuasa, A. Minami et al., “AMP-activated protein kinase is activated by the stimulations of G(q)-coupled receptors,” Biochemical and Biophysical Research Communications, vol. 276, no. 1, pp. 16–22, 2000. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Theodoropoulou, K. Brodowska, M. Kayama et al., “Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastoma in vivo by decreasing angiogenesis and inducing apoptosis,” PLoS ONE, vol. 8, no. 1, Article ID e52852, 2013. View at Publisher · View at Google Scholar
  75. D. L. Williamson, D. C. Butler, and S. E. Alway, “AMPK inhibits myoblast differentiation through a PGC-1α-dependent mechanism,” The American Journal of Physiology: Endocrinology and Metabolism, vol. 297, no. 2, pp. E304–E314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. W. H. Gotlieb, J. Saumet, M.-C. Beauchamp et al., “In vitro metformin anti-neoplastic activity in epithelial ovarian cancer,” Gynecologic Oncology, vol. 110, no. 2, pp. 246–250, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Takiyama, T. Harumi, J. Watanabe et al., “Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism,” Diabetes, vol. 60, no. 3, pp. 981–992, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. J. M. M. Evans, L. A. Donnelly, A. M. Emslie-Smith, D. R. Alessi, and A. D. Morris, “Metformin and reduced risk of cancer in diabetic patients,” British Medical Journal, vol. 330, no. 7503, pp. 1304–1305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. K. Janjetovic, L. Harhaji-Trajkovic, M. Misirkic-Marjanovic et al., “In vitro and in vivo anti-melanoma action of metformin,” European Journal of Pharmacology, vol. 668, no. 3, pp. 373–382, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. G. Wolf and S. J. Shankland, “p27Kip1: the “Rosebud” of diabetic nephropathy?” Journal of the American Society of Nephrology, vol. 14, no. 3, pp. 819–822, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. G. Wolf and F. N. Ziyadeh, “Cellular and molecular mechanisms of proteinuria in diabetic nephropathy,” Nephron Physiology, vol. 106, no. 2, pp. 26–31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. X. Zhang, X. Chen, D. Wu et al., “Downregulation of connexin 43 expression by high glucose induces senescence in glomerular mesangial cells,” Journal of the American Society of Nephrology, vol. 17, no. 6, pp. 1532–1542, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. O. Cazzalini, A. I. Scovassi, M. Savio, L. A. Stivala, and E. Prosperi, “Multiple roles of the cell cycle inhibitor p21CDKN1A in the DNA damage response,” Mutation Research, vol. 704, no. 1–3, pp. 12–20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. Wang, Y. Liang, and P. M. Vanhoutte, “SIRT1 and AMPK in regulating mammalian senescence: a critical review and a working model,” FEBS Letters, vol. 585, no. 7, pp. 986–994, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Morocutti, K. A. Earle, H. P. Rodemann, and G. C. Viberti, “Premature cell ageing and evolution of diabetic nephropathy,” Diabetologia, vol. 40, no. 2, pp. 244–246, 1997. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Morocutti, K. A. Earle, M. Sethi et al., “Premature senescence of skin fibroblasts from insulin-dependent diabetic patients with kidney disease,” Kidney International, vol. 50, no. 1, pp. 250–256, 1996. View at Google Scholar · View at Scopus
  87. D. Verzola, M. T. Gandolfo, G. Gaetani et al., “Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy,” The American Journal of Physiology: Renal Physiology, vol. 295, no. 5, pp. F1563–F1573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. K. Sawai, M. Mukoyama, K. Mori et al., “Redistribution of connexin43 expression in glomerular podocytes predicts poor renal prognosis in patients with type 2 diabetes and overt nephropathy,” Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2472–2477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. L. Liu, X. Hu, G.-Y. Cai et al., “High glucose-induced hypertrophy of mesangial cells is reversed by connexin43 overexpression via PTEN/Akt/mTOR signaling,” Nephrology Dialysis Transplantation, vol. 27, no. 1, pp. 90–100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. P. Atadja, H. Wong, C. Veillete, and K. Riabowol, “Overexpression of cyclin D1 blocks proliferation of normal diploid fibroblasts,” Experimental Cell Research, vol. 217, no. 2, pp. 205–216, 1995. View at Publisher · View at Google Scholar · View at Scopus
  91. T. Yokoi, K. Fukuo, O. Yasuda et al., “Apoptosis signal-regulating kinase 1 mediates cellular senescence induced by high glucose in endothelial cells,” Diabetes, vol. 55, no. 6, pp. 1660–1665, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Vogetseder, T. Palan, D. Bacic, B. Kaissling, and M. Le Hir, “Proximal tubular epithelial cells are generated by division of differentiated cells in the healthy kidney,” The American Journal of Physiology: Cell Physiology, vol. 292, no. 2, pp. C807–C813, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. A. Vogetseder, N. Picard, A. Gaspert, M. Walch, B. Kaissling, and M. Le Hir, “Proliferation capacity of the renal proximal tubule involves the bulk of differentiated epithelial cells,” The American Journal of Physiology: Cell Physiology, vol. 294, no. 1, pp. C22–C28, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Kumazaki, R. S. Robetorye, S. C. Robetorye, and J. R. Smith, “Fibronectin expression increases during in vitro cellular senescence: correlation with increased cell area,” Experimental Cell Research, vol. 195, no. 1, pp. 13–19, 1991. View at Google Scholar · View at Scopus
  95. N. Chondrogianni, F. L. L. Stratford, I. P. Trougakos, B. Friguet, A. J. Rivett, and E. S. Gonos, “Central role of the proteasome in senescence and survival of human fibroblasts. Induction of a senescence-like phenotype upon its inhibition and resistance to stress upon its activation,” Journal of Biological Chemistry, vol. 278, no. 30, pp. 28026–28037, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. D.-S. Jung, S. H. Lee, S.-J. Kwak et al., “Apoptosis occurs differentially according to glomerular size in diabetic kidney disease,” Nephrology Dialysis Transplantation, vol. 27, no. 1, pp. 259–266, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Kumar, S. Robertson, and K. D. Burns, “Evidence of apoptosis in human diabetic kidney,” Molecular and Cellular Biochemistry, vol. 259, no. 1-2, pp. 67–70, 2004. View at Publisher · View at Google Scholar · View at Scopus
  98. M. D. Sanchez-Niñ O, A. B. Sanz, C. Lorz et al., “BASP1 promotes apoptosis in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 21, no. 4, pp. 610–621, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. J. M. Vicencio, L. Galluzzi, N. Tajeddine et al., “Senescence, apoptosis or autophagy? When a damaged cell must decide its path—a mini-review,” Gerontology, vol. 54, no. 2, pp. 92–99, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. M. E. Pagtalunan, P. L. Miller, S. Jumping-Eagle et al., “Podocyte loss and progressive glomerular injury in type II diabetes,” Journal of Clinical Investigation, vol. 99, no. 2, pp. 342–348, 1997. View at Google Scholar · View at Scopus
  101. M. W. Steffes, D. Schmidt, R. McCrery et al., “Glomerular cell number in normal subjects and in type 1 diabetic patients,” Kidney International, vol. 59, no. 6, pp. 2104–2113, 2001. View at Publisher · View at Google Scholar · View at Scopus
  102. Z. N. Demidenko, S. G. Zubova, E. I. Bukreeva, V. A. Pospelov, T. V. Pospelova, and M. V. Blagosklonny, “Rapamycin decelerates cellular senescence,” Cell Cycle, vol. 8, no. 12, pp. 1888–1895, 2009. View at Google Scholar · View at Scopus
  103. S. Cufí, A. Vazquez-Martin, C. Oliveras-Ferraros et al., “Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205,” Cell Cycle, vol. 11, no. 6, pp. 1235–1246, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Law, E. Forrester, A. Chytil et al., “Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes,” Cancer Research, vol. 66, no. 2, pp. 1070–1080, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. A. Salminen and K. Kaarniranta, “AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network,” Ageing Research Reviews, vol. 11, no. 2, pp. 230–241, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. K. R. Hallows, P. F. Mount, N. M. Pastor-Soler, and D. A. Power, “Role of the energy sensor AMP-activated protein kinase in renal physiology and disease,” The American Journal of Physiology: Renal Physiology, vol. 298, no. 5, pp. F1067–F1077, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. R. S. Balaban and L. J. Mandel, “Metabolic substrate utilization by rabbit proximal tubule - an NADH fluorescence,” The American Journal of Physiology: Renal Fluid and Electrolyte Physiology, vol. 254, no. 3, pp. F407–F416, 1988. View at Google Scholar · View at Scopus
  108. L. Meury, J. Noel, A. Tejedor, J. Senecal, A. Gougoux, and P. Vinay, “Glucose metabolism in dog inner medullary collecting ducts,” Renal Physiology and Biochemistry, vol. 17, no. 5, pp. 246–266, 1994. View at Google Scholar · View at Scopus
  109. J. A. Menendez, L. Vellon, C. Oliveras-Ferraros, S. Cufí, and A. Vazquez-Martin, “mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging,” Cell Cycle, vol. 10, no. 21, pp. 3658–3677, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Prigione, B. Fauler, R. Lurz, H. Lehrach, and J. Adjaye, “The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells,” Stem Cells, vol. 28, no. 4, pp. 721–733, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. H. Kondoh, M. E. Lleonart, J. Gil et al., “Glycolytic enzymes can modulate cellular life span,” Cancer Research, vol. 65, no. 1, pp. 177–185, 2005. View at Google Scholar · View at Scopus
  112. I. B. Sahra, Y. L. Marchand-Brustel, J.-F. Tanti, and F. Bost, “Metformin in cancer therapy: a new perspective for an old antidiabetic drug?” Molecular Cancer Therapeutics, vol. 9, no. 5, pp. 1092–1099, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. O. Moiseeva, X. Deschênes-Simard, E. St-Germain et al., “Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation,” Aging Cell, vol. 12, no. 3, pp. 489–498, 2013. View at Publisher · View at Google Scholar
  114. A. A. Alhaider, H. M. Korashy, M. M. Sayed-Ahmed, M. Mobark, H. Kfoury, and M. A. Mansour, “Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression,” Chemico-Biological Interactions, vol. 192, no. 3, pp. 233–242, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. M.-J. Lee, D. Feliers, M. M. Mariappan et al., “A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy,” The American Journal of Physiology: Renal Physiology, vol. 292, no. 2, pp. F617–F627, 2007. View at Publisher · View at Google Scholar · View at Scopus
  116. M. Kaur, G. Deep, A. K. Jain et al., “Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cells,” Carcinogenesis, vol. 34, no. 7, pp. 1585–1592, 2013. View at Publisher · View at Google Scholar
  117. S. Kume, M. C. Thomas, and D. Koya, “Nutrient sensing, autophagy, and diabetic nephropathy,” Diabetes, vol. 61, no. 1, pp. 23–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. R. J. Shaw and L. C. Cantley, “Ancient sensor for ancient drug,” Science, vol. 336, no. 6083, pp. 813–814, 2012. View at Publisher · View at Google Scholar
  119. R. Scacchi, G. Gambina, G. Moretto, and R. M. Corbo, “P21 gene variation and late-onset Alzheimer's disease in the Italian population,” Dementia and Geriatric Cognitive Disorders, vol. 35, no. 1-2, pp. 51–57, 2013. View at Publisher · View at Google Scholar
  120. M. E. Seward, E. Swanson, A. Norambuena et al., “Amyloid-beta signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease,” Journal of Cell Science, vol. 126, no. 5, pp. 1278–1286, 2013. View at Publisher · View at Google Scholar